Fig. 7
From: Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma
Patient-specific response to monotherapy treatment (a). Variations in model proteins were extracted from a cohort of hepatocellular carcinoma (HCC) patients available through The Cancer Genome Atlas (TCGA) (top panel: log2 of fold change in RNA level, n = 50) (b). Percent inhibition of the levels of phosphorylated Akt (pAkt) and pERK was quantified for every patient under each of the four treatments studied here. Each column shows the data for a patient from TCGA, and they are sorted based on the effect of AXT050 on pERK and are aligned for both a and b
